

COMPANY OVERVIEW

A biotech dedicated to developing treatments for unmet medical needs, Unicycive Therapeutics is currently advancing two programs focused on kidney disease and intends to expand its pipeline to target additional indications within and outside kidney disease. Unicycive is preparing to commercialize and launch its lead therapy, oxylanthanum carbonate (OLC), for treatment of hyperphosphatemia in patients with chronic kidney disease and is continuing development of UNI 494 for treatment of acute kidney injury.

INVESTMENT HIGHLIGHTS

Expected commercialization and launch of lead program, OLC, in 2024

- Met primary endpoint in pivotal bioequivalence study in December 2022
- Up to \$130 million financing agreement with leading healthcare funds; includes \$30 million upfront payment in March 2023
- Pursuing a 505(b)(2) regulatory pathway for U.S. approval as per guidance and alignment with the FDA
- Signed out-licensing deal in China with Lee's Pharma for LDC, in Korea with Lotus
- Ongoing out-licensing discussions for OLC with other biopharma partners for other geographies outside the US

Addressing important patient needs and large markets within kidney disease

- Hyperphosphatemia patients live with extreme treatment burden
- No medicines approved for acute kidney injury (AKI) and limited treatment options for patients with chronic kidney disease (CKD)

Product candidates utilizing proven mechanisms of action

- OLC: Phosphate binder for treatment of hyperphosphatemia in patients with CKD
- UNI-494: an innovative patented drug in late preclinical development with a novel mechanism of action that targets mitochondria
- Mitochondrial dysfunction is implicated in acute and chronic disease pathologies in organ systems with high energy demands like the kidney, liver, heart and eye

VALUE PROPOSITION

Unicycive is at the forefront of addressing significant unmet patient needs in kidney disease. With no approved treatments for acute kidney injury and limited options for those with chronic disease, Unicycive is building a pipeline that aims to fill this treatment gap and ultimately improve patient outcomes. According to the National Kidney Foundation, 37 million adults in the US have chronic kidney disease and every year, about 4 million individuals are affected by acute kidney injury.

Unicycive's lead program, OLC, met its primary endpoint in a pivotal bioequivalence study completed in 2022. In March 2023, Unicycive signed a financing agreement with leading healthcare-focused institutional investors (Vivo Capital, RA Capital, BVF Partners, Logos Capital, Nantahala Capital, and Rosalind Advisors) for up to \$130 million to commercialize and launch OLC, including initial upfront funding of \$30 million. The Company expects to file its New Drug Application with the US FDA in 2024 after completing an additional study to evaluate the tolerability of OLC in patients with chronic kidney disease on dialysis.

Unicycive's second program, UNI-494, is designed to restore mitochondrial function and is initially being developed for the treatment of acute kidney injury. This prodrug, a chemically modified form of an existing agent called nicorandil, has improved properties and a lengthy patent life. Nicorandil has been shown to improve clinical outcomes in multiple trials for both acute kidney injury and chronic kidney disease patients. Unicycive is currently preparing to submit its regulatory approval to start a Phase I study of UNI-494.

With multiple near-term catalysts, Unicycive represents a compelling opportunity in the kidney disease space with a valuation that still reflects a significant discount to its peers.

(Nasdaq: UNCY)

Unicycive Therapeutics, Inc.

HQ: Los Altos, CA

Leadership Team

Chairman & CEO: Shalabh Gupta, MD

CFO: John Townsend

EVP Corporate Strategy: Doug Jermasek

VP Preclinical R&D: Guru Reddy, PhD

Auditors: Mayer Hoffman McCan

Legal: Shepard, Mullin, Richter & Hampton

MARKET DATA

Price ¹	\$0.82
Market Cap ¹	\$12.5M
Shares Outstanding ¹	15.2M
Float ¹	8.7M
Insider Ownership ¹	41.7%
Cash (mrq) ²	\$18.8M
LT Debt (mrq) ²	\$0

Fiscal Year: December 31

¹ as of August 14, 2023

² as of June 30, 2023

Top Institutional Owners

Rosalind Advisors	970k
Nantahala Capital	650k
Altium Growth	180k
Stanford Management	60k

www.unicycive.com